Susquehanna International Group
CRVS icon

Susquehanna International Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Susquehanna International Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$565K Sell
38,636
-23,118
-37% -$369K ﹤0.01% 9352
2025
Q4 		$476K Buy
+61,754
New +$487K ﹤0.01% 8907
2025
Q3 		– Sell
-67,816
Closed -$347K – 12602
2025
Q2 		$271K Sell
67,816
-883,527
-93% -$3.21M ﹤0.01% 10574
2025
Q1 		$3.03M Sell
951,343
-63,740
-6% -$300K ﹤0.01% 4632
2024
Q4 		$5.43M Buy
1,015,083
+796,121
+364% +$5.94M ﹤0.01% 3465
2024
Q3 		$1.16M Buy
218,962
+193,312
+754% +$694K ﹤0.01% 6459
2024
Q2 		$46.7K Sell
25,650
-79,376
-76% -$148K ﹤0.01% 11438
2024
Q1 		$187K Sell
105,026
-115,270
-52% -$241K ﹤0.01% 10670
2023
Q4 		$388K Buy
220,296
+92,328
+72% +$135K ﹤0.01% 9261
2023
Q3 		$187K Sell
127,968
-67,284
-34% -$142K ﹤0.01% 10310
2023
Q2 		$447K Buy
195,252
+184,809
+1,770% +$384K ﹤0.01% 8574
2023
Q1 		$9.5K Buy
+10,443
New +$8.15K ﹤0.01% 12218
2022
Q2 		– Sell
-48,283
Closed -$59.2K – 13023
2022
Q1 		$79K Sell
48,283
-27,435
-36% -$50.2K ﹤0.01% 12061
2021
Q4 		$182K Sell
75,718
-12,579
-14% -$48.8K ﹤0.01% 11558
2021
Q3 		$427K Buy
88,297
+52,591
+147% +$156K ﹤0.01% 9783
2021
Q2 		$95K Sell
35,706
-55,532
-61% -$153K ﹤0.01% 12116
2021
Q1 		$281K Buy
91,238
+75,557
+482% +$273K ﹤0.01% 10752
2020
Q4 		$56K Buy
+15,681
New +$63.1K ﹤0.01% 10716
2020
Q2 		– Sell
-117,606
Closed -$248K – 10209
2020
Q1 		$248K Buy
117,606
+49,700
+73% +$202K ﹤0.01% 8324
2019
Q4 		$369K Buy
+67,906
New +$238K ﹤0.01% 7590

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Susquehanna International Group's CRVS Position: Q1 2026 in Review

Susquehanna International Group reduced its Corvus Pharmaceuticals (CRVS) stake by 37% in Q1 2026, selling an estimated $369K and leaving 38,636 shares worth $565K. The position accounts for ﹤0.01% of the portfolio, ranked #9352.

Susquehanna International Group first reported a position in CRVS in Q4 2019 and has held it in 20 quarters since. The position peaked at $5.43M in Q4 2024. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Susquehanna International Group held 38,636 shares of Corvus Pharmaceuticals worth $565K as of Q1 2026.
  • Susquehanna International Group sold 23,118 Corvus Pharmaceuticals shares in Q1 2026, an estimated $369K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9352 holding.
  • Susquehanna International Group first reported a position in Corvus Pharmaceuticals in Q4 2019 and has held it in 20 quarters since.
  • Susquehanna International Group's Corvus Pharmaceuticals position peaked at $5.43M in Q4 2024.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.